Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eton PharmaceuticalsETON +44.55%57 PS Ratio is 16.53 as of Aug. 14, 2026, which is 111% above its 10-year median of 7.82. GuruFocus rates ETON with a GF Score™ of 57/100 and a GF Value™ of $19.98 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 951 Drug Manufacturers companies, Eton Pharmaceuticals ranks worse than 90.22% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Eton Pharmaceuticals's share price is $58.51.
Eton Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $3.54. Hence, Eton Pharmaceuticals's PS Ratio for today is 16.53.
The historical rank and industry rank for Eton Pharmaceuticals's PS Ratio or its related term are showing as below:
ETON'
s PS Ratio Range Over the Past 10 Years
Min: 2.25 Med: 7.82 Max: 10000
Current: 19.03
During the past 9 years, Eton Pharmaceuticals's highest PS Ratio was 10000.00. The lowest was 2.25. And the median was 7.82.
ETON's PS Ratio is ranked worse than 90.22% of 951
companies
in the Drug Manufacturers industry
Industry Median: 2.33
vs ETON: 19.03
Eton Pharmaceuticals Inc revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Eton Pharmaceuticals was 69.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 52.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 200.90% per year.
During the past 9 years, Eton Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 751.30% per year. The lowest was 20.30% per year. And the median was 101.10% per year.
Eton Pharmaceuticals (NAS:ETON) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Eton Pharmaceuticals PS Ratio Related Terms
Eton Pharmaceuticals PS Ratio Historical Data
* Premium members only.
The historical data trend for Eton Pharmaceuticals's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Eton Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eton Pharmaceuticals PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eton Pharmaceuticals's PS Ratio distribution charts can be found below:
* The bar in red indicates where Eton Pharmaceuticals's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Eton Pharmaceuticals's Share Price of today is $58.51. Eton Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.54.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Eton Pharmaceuticals (ETON) has a PS Ratio of 16.53 as of Aug. 14, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Eton Pharmaceuticals and its competitors. This is 111% above median its historical median of 7.82. Over the past decade, Eton Pharmaceuticals' PS Ratio has ranged from 2.25 to 10,000.00. According to the industry distribution chart, Eton Pharmaceuticals ranks #858 out of 951 companies in the Drug Manufacturers industry, placing it in the top 90.2%.
Is Eton Pharmaceuticals' PS Ratio too high?
Eton Pharmaceuticals' current PS Ratio of 16.53 is 111% above median its 10-year median of 7.82. Over the past 10 years, this metric has ranged from a low of 2.25 to a high of 10,000.00. The Drug Manufacturers industry median PS Ratio is 2.33. Eton Pharmaceuticals' value of 16.53 is 609.4% above this industry median. Based on the distribution chart, Eton Pharmaceuticals ranks #858 out of 951 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Eton Pharmaceuticals has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Eton Pharmaceuticals' PS Ratio compare to COLL and ALVO?
According to the Drug Manufacturers industry distribution chart, Eton Pharmaceuticals ranks #858 out of 951 companies for PS Ratio. This places Eton Pharmaceuticals in the lower half of its industry. The industry median PS Ratio is 2.33. Eton Pharmaceuticals' value of 16.53 is 609.4% above this benchmark. Historically, Eton Pharmaceuticals' own PS Ratio has ranged from 2.25 to 10,000.00 over the past decade. While the company's 10-year median is 7.82 vs. the industry median of 2.33, Eton Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.33, based on 951 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eton Pharmaceuticals's current PS Ratio of 16.53 is 609.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Eton Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eton Pharmaceuticals's current PS Ratio is 16.53, which is 111% above median its own 10-year median of 7.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eton Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Eton Pharmaceuticals (ETON) is currently considered Significantly Overvalued. The stock's GF Value™ is $19.98, compared to a current price of $58.51 — trading 192.8% above its estimated fair value. The current PS Ratio is 16.53, which is 111% above median its 10-year median of 7.82 and 609.4% above the Drug Manufacturers industry median of 2.33. Eton Pharmaceuticals' overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Eton Pharmaceuticals (ETON), the current PS Ratio is 16.53 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eton Pharmaceuticals (ETON) Overvalued in 2026?
Based on GuruFocus' analysis, Eton Pharmaceuticals stock appears to be overvalued.
The current stock price of $58.51 is trading 192.8% above its estimated GF Value™ of $19.98.
GuruFocus considers Eton Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for ETON:
PS Ratio: 16.53 (111% above median its 10-year median of 7.82)
GF Value™: $19.98 vs. price of $58.51 (192.8% above fair value)
Industry Position: 609.4% above the Drug Manufacturers median (#858 of 951)
No single metric tells the full story. See the ETON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.
57GF Score
Get the complete analysis for ETON
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ETON has been successfully added to your 
